Highlights GenKyoTex SA Euronext Paris

Equities

GKTX

FR0011790542

End-of-day quote Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-.--%

2021	Calliditas Therapeutics : Acquires Remaining Stake in Genkyotex	MT
2021	Genkyotex SA(ENXTPA:GKTX) dropped from CAC AllShares Index	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Calliditas Therapeutics : Acquires Remaining Stake in Genkyotex	07/21/07	MT
Global markets live: Sanofi, ASML, Apple, United Airlines, Netflix...	29/21/29
Genkyotex Sa Reports Earnings Results for the Full Year Ended December 31, 2020	18/21/18	CI
Genkyotex SA Announces Update for Near Term Clinical Development Plan for Setanaxib	22/21/22	CI
Genkyotex Announces Positive Phase 1 Results Demonstrating Favorable Safety and Pharmacokinetic Profile of High-Dose Setanaxib	18/21/18	CI
Calliditas Therapeutics AB (OM:CALTX) completed the acquisition of 37.3% stake in Genkyotex SA.	11/20/11	CI
Genkyotex : Setanaxib Obtains Orphan Drug Designation By European Commission	08/20/08	MT
Genkyotex Sa Reports Earnings Results for the Half Year Ended June 30, 2020	17/20/17	CI
Genkyotex Announces the Enrollment of the 1st Patient in the Phase 2 Trial of Setanaxib in Idiopathic Pulmonary Fibrosis	14/20/14	CI
Calliditas Therapeutics AB (OM:CALTX) made a tender offer to acquire 37.3% stake in Genkyotex SA for €12.1 million.	13/20/13	CI
Genkyotex Announces the Dosing of the First Subjects in Its Phase 1 Study with High-Dose Setanaxib	30/20/30	CI
Genkyotex Provides New Clinical Data from the PBC Phase 2 Trial Providing Further Evidence of the Anti-Fibrotic Activity of Setanaxib	18/20/18	CI
Genkyotex Receives Approval From the French Medicines Agency to Initiate a Phase 1 Clinical Study With High-dose Setanaxib	13/20/13	CI
Genkyotex SA Announces Consolidated Earnings Results for the Year Ended December 31, 2019	05/20/05	CI
Genkyotex’s Setanaxib Significantly Improves Immunotherapy Including Checkpoint Inhibitors in Multiple Preclinical Cancer Models	03/20/03	CI
Genkyotex Sa Reports Earnings Results for the Full Year Ended December 31, 2019	27/20/27	CI
Genkyotex Reports Progress of Setanaxib Phase 2 Investigator Initiated Trials	03/19/03	CI
Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF	17/19/17	CI
Genkyotex Announces the Publication of Data in Clinics and Research in Hepatology and Gastroenterology	01/19/01	CI
Genkyotex Announces the Final Results of Its Phase 2 Trial of GKT831 in Primary Biliary Cholangitis	24/19/24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GenKyoTex SA Euronext Paris

Equities

GKTX

FR0011790542

Highlights

Filters